Vascular risk factors as treatment target to prevent cognitive decline

Edo Richard1, Eric P Moll van Charante, Willem A van Gool

  • 1Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. e.richard@amc.uva.nl

Insights

Vascular risk factors increase dementia risk, but trials treating single factors haven't prevented cognitive decline. New trials targeting multiple factors are needed to determine if prevention is possible.

Area of Science:

  • Neurology
  • Epidemiology
  • Gerontology

Background:

  • Vascular risk factors like hypertension and diabetes are linked to cognitive decline and dementia.
  • Cerebrovascular lesions play a key role in the development of late-onset dementia.

Purpose of the Study:

  • To review the literature on the effectiveness of treating vascular risk factors for preventing cognitive decline and dementia.
  • To discuss methodological challenges in designing future randomized controlled trials (RCTs) for dementia prevention.

Main Methods:

  • Literature review of epidemiological, neuroradiological, neuropathological, and clinical trial studies.
  • Analysis of existing randomized controlled trials (RCTs) assessing cognitive outcomes.
  • Discussion of optimal design considerations for future RCTs.

Main Results:

  • Epidemiological studies consistently associate vascular risk factors with increased dementia risk.
  • Current RCTs targeting individual vascular risk factors have not convincingly demonstrated prevention or postponement of cognitive decline or dementia.
  • Neuroradiological and neuropathological studies highlight the significance of cerebrovascular lesions in dementia etiology.

Conclusions:

  • Treatment of individual vascular risk factors has not yet proven effective in preventing cognitive decline or dementia.
  • Future RCTs should target multiple vascular risk factors concurrently and use cognitive decline or dementia as primary outcomes.
  • Designing effective RCTs requires careful consideration of methodological issues and long follow-up periods.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.